3rd Joint DIA-EUCOPE Workshop on ATMPs, Innovative Gene and Cell Therapies in the EU

The recent wave of approved ATMPs has ignited a renaissance within the pharmaceutical / biotech industry. Numerous other ATMPs are currently underway to further broaden the spectrum of indications that these innovative products intend to treat. The development pipeline also displays how rapid the underlying technologies of these medicinal products is evolving and forecasts exciting and novel avenues of treatment for patients.

Within this session we will explore the latest technologies with ATMP-relevance that are in development and try to gain an insight of what the field might hold within its future. Additionally, we would like to invite the participants from different areas (academia, regulators and industry) to discuss with us what opportunities and challenges we might encounter with these novel technologies. This session is not only open for everybody with a regulatory, evidence or access background but we would also like to welcome ATMP enthusiasts that want to learn what is currently going-on within this fast-paced field.

Topics explored in this Session:

• Novel technologies intended for ATMPs:

- 2nd Generation Gene Editing/ Base Editing.

- New Technology to develop CAR-T Cells.

• The road from Innovation to Clinical Trials.
• Where will the field be in 10 years?
• Challenges and opportunities emerging with these innovative technologies.